FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPAR and PPAR Agonists
In the obese trial cohort, 1 mg moved 24-hour ambulatory heart rate by +0.7 bpm at week 24 the peak of the heart-rate curve, and below the placebo arms +0.8. In a healthy lean Phase 1 group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Medically reviewed by Patricia Hartke, Pharm.D., BCPS Last update: April 22, 2026 Est
Heres more about why we prefer Limitless Life : Independent Lab Verification of Quality: Limitless Life is able to ensure product quality, purity, and potency by offering third-party lab testing on each product
Blood 12:603, 1957